CARDIOL THERAPEUTICS INC-A (CRDL.CA) Stock Price, Forecast & Analysis
Canada • Toronto Stock Exchange • TSX:CRDL • CA14161Y2006
CRDL.CA Key Statistics, Chart & Performance
The current stock price of CRDL.CA is 1.28 CAD. In the past month the price decreased by -5.88%. In the past year, price decreased by -37.25%.
CRDL.CA Technical Analysis
CRDL.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CRDL.CA. While CRDL.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
CRDL.CA Financial Highlights
Over the last trailing twelve months CRDL.CA reported a non-GAAP Earnings per Share(EPS) of -0.41. The EPS increased by 24.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -268.65% | ||
| ROE | -363.82% | ||
| Debt/Equity | 0.01 |
CRDL.CA Forecast & Estimates
8 analysts have analysed CRDL.CA and the average price target is 9.59 CAD. This implies a price increase of 649.06% is expected in the next year compared to the current price of 1.28.
CRDL.CA Ownership
About CRDL.CA
Company Profile
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company is headquartered in Oakville, Ontario and currently employs 18 full-time employees. The company went IPO on 2018-12-20. The firm's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. The company holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The firm is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Company Info
CARDIOL THERAPEUTICS INC-A
602-2265 Upper Middle Road East
Oakville ONTARIO L6H 0G5 CA
CEO: David G. Elsley
Employees: 18
Phone: 12899100850
CARDIOL THERAPEUTICS INC-A / CRDL.CA FAQ
What does CARDIOL THERAPEUTICS INC-A do?
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company is headquartered in Oakville, Ontario and currently employs 18 full-time employees. The company went IPO on 2018-12-20. The firm's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. The company holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The firm is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
What is the stock price of CARDIOL THERAPEUTICS INC-A today?
The current stock price of CRDL.CA is 1.28 CAD. The price decreased by -2.29% in the last trading session.
What is the dividend status of CARDIOL THERAPEUTICS INC-A?
CRDL.CA does not pay a dividend.
How is the ChartMill rating for CARDIOL THERAPEUTICS INC-A?
CRDL.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Should I buy CRDL stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CRDL.CA.
What is CARDIOL THERAPEUTICS INC-A worth?
CARDIOL THERAPEUTICS INC-A (CRDL.CA) has a market capitalization of 127.35M CAD. This makes CRDL.CA a Micro Cap stock.